Here are the 10-K annual reports from Vir Biotechnology, Inc. (VIR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIR filings page.
Vir Biotechnology is a clinical-stage biopharma company focused on serious infectious diseases and cancer, using antibody discovery, AI-enabled engineering and the PRO-XTEN® masking platform to power the immune system against viruses and solid tumors.
The company’s lead program is the tobevibart and elebsiran combination for chronic hepatitis delta, where Phase 2 data showed high rates of undetectable HDV RNA and hepatitis B surface antigen suppression, and three registrational ECLIPSE trials are underway with topline results expected in late 2026 and early 2027. Vir has also decided not to move this combination into Phase 3 for chronic hepatitis B after mixed cure-rate data.
In oncology, Vir is advancing three dual-masked T-cell engagers—VIR-5500 for prostate cancer, VIR-5818 for HER2-positive tumors, and VIR-5525 for EGFR-expressing tumors—with early Phase 1 data showing dose-dependent tumor shrinkage and manageable cytokine release. A broad preclinical pipeline of additional PRO-XTEN® TCEs targets multiple solid tumors.
The company strengthened its partnering base through multiple strategic deals. A global collaboration with Astellas around VIR-5500 includes $335 million in upfront and near-term consideration, shared global development costs, equal U.S. profit-sharing and significant future milestones and royalties. A license with Norgine brought €55 million in initial development cost reimbursement plus up to €495 million in milestones and mid-teen to high-twenties percent royalties for the hepatitis delta combination in Europe, Australia and New Zealand. Vir also licensed the PRO-XTEN® technology and three masked TCEs from Sanofi for $100 million upfront and a $75 million milestone tied to first-in-human dosing of VIR-5525, with substantial future milestones and royalties, and maintains legacy collaborations with GSK, Alnylam, Brii Biosciences, the Gates Foundation and others that support its infectious disease pipeline.